Sphingosine Kinase-1 Activation Causes Acquired Resistance Against Sunitinib in Renal Cell Carcinoma Cells

Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting

(2012) Olivier Cuvillier et al.   Current Molecular Pharmacology

Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines

(2011) H Li et al.   Advances in Medical Sciences

Sunitinib and other targeted therapies for renal cell carcinoma

(2011) T Powles et al.   BRITISH JOURNAL OF CANCER

Immunotherapy for Renal Cell Carcinoma

(2011) Momoe Itsumi et al.   Clinical & Developmental Immunology

Sphingosine Kinase-1 Enhances Resistance to Apoptosis through Activation of PI3K/Akt/NF- B Pathway in Human Non-Small Cell Lung Cancer

(2011) L. Song et al.   CLINICAL CANCER RESEARCH

Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells

(2011) Gabriella Marfe et al.   EXPERIMENTAL HEMATOLOGY

Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1α inactivation in hypoxic PC-3 prostate cancer cells

(2011) Sung-Yun Cho et al.   JOURNAL OF PINEAL RESEARCH

Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer

(2011) Dmitri Pchejetski et al.   Nature Reviews Urology

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors

(2011) Floriana Morgillo et al.   PLoS One

Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma

(2011) P. Olson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

(2010) D. Huang et al.   CANCER RESEARCH

Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma

(2010) D. Huang et al.   CANCER RESEARCH

Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells

(2010) E. Martinelli et al.   CLINICAL CANCER RESEARCH

Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells

(2009) H. Xin et al.   CANCER RESEARCH

Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters

(2009) S. Hu et al.   CLINICAL CANCER RESEARCH

Activated Akt Prevents Antitumor Activity of Gefitinib in Renal Cancer Cells

(2009) Kenji Kuroda et al.   UROLOGY

Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2

(2008) S. Shukla et al.   DRUG METABOLISM AND DISPOSITION